The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response

BACKGROUND: Circulating cell-free DNA (cfDNA) may help understand the molecular response to pharmacologic treatment and provide information on dynamics of clonal heterogeneity. Therefore, this study evaluated the correlation between treatment outcome and activating EGFR mutations (act-EGFR) and T790...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Br J Cancer
Prif Awduron: Del Re, Marzia, Bordi, Paola, Rofi, Eleonora, Restante, Giuliana, Valleggi, Simona, Minari, Roberta, Crucitta, Stefania, Arrigoni, Elena, Chella, Antonio, Morganti, Riccardo, Tiseo, Marcello, Petrini, Iacopo, Danesi, Romano
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group UK 2018
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6251035/
https://ncbi.nlm.nih.gov/pubmed/30397287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0238-z
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg